23
Participants
Start Date
July 10, 2010
Primary Completion Date
September 4, 2014
Study Completion Date
October 26, 2017
RAD001 (Everolimus)
"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
New York University Medical Center, New York
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
National Cancer Institute, Bethesda
Indiana University, Indianapolis
Children's Lurie Hospital, Chicago
University of Chicago, Chicago
Washington University, St Louis
University of Utah, Salt Lake City
Children's Hospital Los Angeles, Los Angeles
Children's Hospital Boston, Boston
Cincinnati Children's Hospital Medical Center, Cincinnati
Collaborators (1)
Boston Children's Hospital
OTHER
Children's Hospital of Philadelphia
OTHER
Children's National Research Institute
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
National Cancer Institute (NCI)
NIH
University of Chicago
OTHER
University of Utah
OTHER
Washington University School of Medicine
OTHER
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
NYU Langone Health
OTHER
Children's Hospital Los Angeles
OTHER
University of Alabama at Birmingham
OTHER